DELFI

What is DELFI Diagnostics?

DELFI Diagnostics is a cancer detection company that uses AI and whole-genome sequencing to analyze DNA fragmentation patterns in blood, capturing signals that conventional liquid biopsy approaches often miss. Its platform supports both early cancer screening and drug development research, from biomarker discovery to treatment monitoring.

What is fragmentomics?

Fragmentomics is the study of cell-free DNA fragment patterns in blood. Cancer cells package DNA abnormally, creating distinctive patterns when the cells die and release DNA into the bloodstream.

What is FirstLook Lung?

FirstLook Lung is a blood-based laboratory-developed test that uses AI and whole genome sequencing to help identify individuals who should be referred to low-dose computed tomography (LDCT). It is intended for people eligible for lung cancer screening under USPSTF guidelines — adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. It is available through select health systems and healthcare providers.

What is the clinical performance of FirstLook Lung?

FirstLook Lung has a Negative Predictive Value of 99.8%, so 998 out of 1000 people with a Not Elevated result will not have lung cancer detected on LDCT. For those with an Elevated result, the likelihood of finding lung cancer on LDCT is 5.2 times higher, and the Number Needed to Screen drops from 143 to 79.